NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Nave or Resistant R/M-HNSCC
Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients…
Silynxcom Announces First Half of 2025 Financial Results, Expands Client Diversity and Raised $2.9M to Support Growth
September 26, 2025 16:05 ET | Source: Silynxcom Ltd. Netanya, Israel, Sept.…
Maris-Tech Announces Financial Results for the Six Months Ended June 30, 2025
September 26, 2025 16:04 ET | Source: Maris-Tech Ltd. The company continues…
Medicenna Announces Results of Annual Meeting of Shareholders
TORONTO and HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or…
Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
September 25, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…
Verano to Report Third Quarter 2025 Financial Results on October 29, 2025
CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA:…
Euro NCAP to Launch New 2025 Assisted Driving Results
WhatLatest Euro NCAP AD results published online and via social media.WhenWednesday 24 September - 11:00…
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
Ad hoc announcement pursuant to Art. 53 LR A conference call will…
MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22
September 19, 2025 16:18 ET | Source: MBX Biosciences, Inc. CARMEL, Ind.,…
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…
